Le Lézard
Classified in: Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Letter

Comtech Announces Results for its Second Quarter of Fiscal 2024


March 18, 2024-- Comtech (NASDAQ: CMTL) ("the Company") today announced its second quarter fiscal 2024 financial results in a letter to shareholders, which has been posted to the Investor Relations section of Comtech's website.

Investors are invited to access the second quarter fiscal 2024 shareholder letter at comtech.com/investors/. A copy of the letter will also be filed with the Securities and Exchange Commission in a Form 8-K.

Comtech will host its previously scheduled earnings conference call at 5:00 PM ET today. In light of the Company's recent leadership transition, it will not be taking Q&A on the call. The call may be accessed by dialing (800) 225-9448 (domestic) or (203) 518-9708 (international) and using the conference I.D. of "Comtech." A replay of the call will be available by dialing (888) 566-0825 or (402) 220-0427 through Monday, April 1, 2024. A live webcast of the call is also available at comtech.com/investors/.

About Comtech

Comtech Telecommunications Corp. is a leading global technology company providing terrestrial and wireless network solutions, next-generation 9-1-1 emergency services, satellite and space communications technologies, and cloud native capabilities to commercial and government customers around the world. Our unique culture of innovation and employee empowerment unleashes a relentless passion for customer success. With multiple facilities located in technology corridors throughout the United States and around the world, Comtech leverages our global presence, technology leadership, and decades of experience to create the world's most innovative communications solutions. For more information, please visit www.comtech.com.

Forward-Looking Statements

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company's Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward- looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings.


These press releases may also interest you

at 07:35
SolarWinds Enhances Plan Explorer to Help Database Pros Improve Operations, Performance, and Business Outcomes
SolarWinds , a leading provider of simple, powerful, secure observability and IT management software, recently announced enhancements to Plan Explorer®, its tool for analyzing query performance in Microsoft® SQL Server® environments. This free...

at 07:35
NeoGenomics Reports First Quarter 2024 Results
NeoGenomics, Inc. (the "Company"), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights   Consolidated revenue...

at 07:35
Survey: Human Factors Create Significant Cybersecurity Risks for Small and Medium-Sized Businesses, Despite Increased Technology Investment
Small and medium-sized business (SMB) leaders report that they are investing more time, attention, and budget on cybersecurity, but human factors are getting in the way ? including lack of awareness, training and inconsistent policy adherence....

at 07:35
908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering
908 Devices Inc. , a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biochemical analysis, announces that it has completed the acquisition of privately-held RedWave Technology, a leading provider of portable FTIR...

at 07:35
TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
TriLink BioTechnologies (TriLink®), a Maravaitm LifeSciences company and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the...

at 07:35
Virpax Announces Results of Maximum Tolerated Dose Study for Probudurtm
Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications,...

More news about Science and technology...


News published on and distributed by: